Published : Oct-2017
No. of Pages : 235
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Introduction 12
2.1 Wound Closure Hemostats Overview 12
3 Products under Development 13
3.1 Wound Closure Hemostats - Pipeline Products by Stage of Development 13
3.2 Wound Closure Hemostats - Pipeline Products by Segment 14
3.3 Wound Closure Hemostats - Pipeline Products by Territory 15
3.4 Wound Closure Hemostats - Pipeline Products by Regulatory Path 16
3.5 Wound Closure Hemostats - Pipeline Products by Estimated Approval Date 17
3.6 Wound Closure Hemostats - Ongoing Clinical Trials 18
4 Wound Closure Hemostats - Pipeline Products under Development by Companies 19
4.1 Wound Closure Hemostats Companies - Pipeline Products by Stage of Development 19
4.2 Wound Closure Hemostats - Pipeline Products by Stage of Development 21
5 Wound Closure Hemostats Companies and Product Overview 23
5.1 3-D Matrix Ltd Company Overview 23
5.1.1 3-D Matrix Ltd Pipeline Products & Ongoing Clinical Trials Overview 23
5.2 Anika Therapeutics Inc Company Overview 28
5.2.1 Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 28
5.3 Arch Therapeutics Inc Company Overview 29
5.3.1 Arch Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 29
5.4 Argon Medical Devices Inc Company Overview 31
5.4.1 Argon Medical Devices Inc Pipeline Products & Ongoing Clinical Trials Overview 31
5.5 Baxter International Inc Company Overview 32
5.5.1 Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview 32
5.6 Beth Israel Deaconess Medical Center Inc Company Overview 36
5.6.1 Beth Israel Deaconess Medical Center Inc Pipeline Products & Ongoing Clinical Trials Overview 36
5.7 Biomedica Management Corp Company Overview 37
5.7.1 Biomedica Management Corp Pipeline Products & Ongoing Clinical Trials Overview 37
5.8 Biom'Up SAS Company Overview 40
5.8.1 Biom'Up SAS Pipeline Products & Ongoing Clinical Trials Overview 40
5.9 C. R. Bard Inc Company Overview 43
5.9.1 C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 43
5.10 Cellphire Inc Company Overview 45
5.10.1 Cellphire Inc Pipeline Products & Ongoing Clinical Trials Overview 45
5.11 Ceramicos Para Aplicacoes Medicas Lda Company Overview 47
5.11.1 Ceramicos Para Aplicacoes Medicas Lda Pipeline Products & Ongoing Clinical Trials Overview 47
5.12 Columbia University Company Overview 48
5.12.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 48
5.13 Covalent Medical, Inc. (Inactive) Company Overview 49
5.13.1 Covalent Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 49
5.14 Covalon Technologies Ltd Company Overview 50
5.14.1 Covalon Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 50
5.15 Cresilon Inc Company Overview 52
5.15.1 Cresilon Inc Pipeline Products & Ongoing Clinical Trials Overview 52
5.16 CryoLife Inc Company Overview 54
5.16.1 CryoLife Inc Pipeline Products & Ongoing Clinical Trials Overview 54
5.17 Endomedix Incorporated Company Overview 57
5.17.1 Endomedix Incorporated Pipeline Products & Ongoing Clinical Trials Overview 57
5.18 Entegrion Inc Company Overview 59
5.18.1 Entegrion Inc Pipeline Products & Ongoing Clinical Trials Overview 59
5.19 Ethicon US LLC Company Overview 60
5.19.1 Ethicon US LLC Pipeline Products & Ongoing Clinical Trials Overview 60
5.20 Gamma Therapeutics Inc Company Overview 63
5.20.1 Gamma Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 63
5.21 gel-e Inc Company Overview 64
5.21.1 gel-e Inc Pipeline Products & Ongoing Clinical Trials Overview 64
5.22 Haemostatix Ltd Company Overview 66
5.22.1 Haemostatix Ltd Pipeline Products & Ongoing Clinical Trials Overview 66
5.23 Hemostasis LLC Company Overview 70
5.23.1 Hemostasis LLC Pipeline Products & Ongoing Clinical Trials Overview 70
5.24 KeraNetics, LLC Company Overview 72
5.24.1 KeraNetics, LLC Pipeline Products & Ongoing Clinical Trials Overview 72
5.25 LifeBond Ltd Company Overview 73
5.25.1 LifeBond Ltd Pipeline Products & Ongoing Clinical Trials Overview 73
5.26 Resorba GmbH Company Overview 76
5.26.1 Resorba GmbH Pipeline Products & Ongoing Clinical Trials Overview 76
5.27 Rice University Company Overview 81
5.27.1 Rice University Pipeline Products & Ongoing Clinical Trials Overview 81
5.28 Samyang Biopharmaceuticals Corp Company Overview 82
5.28.1 Samyang Biopharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview 82
5.29 Sanofi Company Overview 83
5.29.1 Sanofi Pipeline Products & Ongoing Clinical Trials Overview 83
5.30 Sea Run Holdings Inc Company Overview 85
5.30.1 Sea Run Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 85
5.31 St Teresa Medical Inc Company Overview 86
5.31.1 St Teresa Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 86
5.32 The Medicines Company Company Overview 88
5.32.1 The Medicines Company Pipeline Products & Ongoing Clinical Trials Overview 88
5.33 Therus Corporation Company Overview 89
5.33.1 Therus Corporation Pipeline Products & Ongoing Clinical Trials Overview 89
5.34 Thrombotargets Corp Company Overview 90
5.34.1 Thrombotargets Corp Pipeline Products & Ongoing Clinical Trials Overview 90
5.35 United Health Products, Inc. Company Overview 92
5.35.1 United Health Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview 92
5.36 University of Grenoble Alpes Company Overview 95
5.36.1 University of Grenoble Alpes Pipeline Products & Ongoing Clinical Trials Overview 95
5.37 Virginia Commonwealth University Company Overview 96
5.37.1 Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview 96
5.38 Wound Management Technologies Inc Company Overview 97
5.38.1 Wound Management Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 97
5.39 Xcede Technologies Inc Company Overview 98
5.39.1 Xcede Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 98
6 Wound Closure Hemostats - Recent Developments 101
6.1 Sep 13, 2017: Advanced Medical Solutions: Interim Results for the six months ended 30 June 2017 101
6.2 Sep 13, 2017: gel-e Expands Core Team with Regulatory, Manufacturing and Financial Talent 101
6.3 Sep 12, 2017: Arch Therapeutics Reports Favorable Results in Repeat Dose Testing of AC5 for Subchronic Systemic Toxicity 102
6.4 Sep 07, 2017: St. Teresa Medical Announces First Commercial Use of SURGICLOT in Auckland, New Zealand 102
6.5 Aug 28, 2017: Anika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs 103
6.6 Aug 22, 2017: United Health Products Reports Second Quarter 2017 Results 104
6.7 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 104
6.8 Aug 21, 2017: Covalon Releases Third Quarter Financial Results 107
6.9 Aug 09, 2017: The Medicines Company Reports Second Quarter 2017 Business and Financial Results 107
6.10 Aug 09, 2017: Novadaq Receives Court Approval for Arrangement With Stryker 110
6.11 Aug 02, 2017: United Health Products Reports Profitable First Quarter ended March 31, 2017 110
6.12 Aug 02, 2017: Stryker announces election of new Director, Mary K. Brainerd 111
6.13 Jul 31, 2017: Advanced Medical Solutions Group Reports H1 2016 Results 111
6.14 Jul 31, 2017: Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER 111
6.15 Jul 31, 2017: Dr. Joachim Schulz joins the Management Board of B. Braun Melsungen 118
6.16 Jul 28, 2017: Indonesian Minister of Health Launches New German Pharmaceutical Factory in Karawang 119
6.17 Jul 27, 2017: Stryker reports second quarter 2017 results 119
6.18 Jul 27, 2017: Anika Announces Appointment of Joseph Darling as President 120
6.19 Jul 26, 2017: Baxter Reports Second-Quarter 2017 Results and Provides Updated Financial Outlook for 2017 and 2020 121
6.20 Jul 26, 2017: Merit Medical Reports Record Revenue and Non-GAAP Net Income for Second Quarter 2017, Raises 2017 Guidance and Gives Preliminary 2018-2019 Guidance 123
6.21 Jul 26, 2017: Anika Reports Strong Second Quarter 2017 Financial Results 124
6.22 Jul 25, 2017: Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5 Topical Gel 125
6.23 Jul 24, 2017: Ergomed completes Phase IIb study recruitment six months ahead of schedule for its innovative coagulant PeproStat 126
6.24 Jul 24, 2017: CryoLife Reports Second Quarter 2017 Financial Results 127
6.25 Jul 20, 2017: Wound Management Technologies Announces Q2 2017 Sales Up 15% over Q2 2016 and All Amortized Debt Retired in the Second Quarter 128
6.26 Jul 18, 2017: Johnson & Johnson Reports 2017 Second-Quarter Results 128
6.27 Jul 17, 2017: Baxter Appoints Cathy R. Smith to its Board 130
6.28 Jul 12, 2017: Sanofi: Pre-quarterly Results Communication 130
6.29 Jun 21, 2017: PeproStat Phase IIb study passes recruitment mid-point ahead of schedule - Top line results brought forward to Q4 2017 132
6.30 Jun 08, 2017: B. Braun is participating in the third edition of the High-Tech Founders Fund 133
6.31 Jun 06, 2017: Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017 133
6.32 Jun 06, 2017: Ethicon Announces FDA Approval For SURGICEL Powder Absorbable Hemostat 134
6.33 Jun 06, 2017: Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017 135
6.34 May 29, 2017: Covalon Releases Second Quarter Financial Results 135
6.35 May 26, 2017: Merit Medical Announces Appointment of New Director 136
6.36 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 136
6.37 May 17, 2017: Wound Management Issues 2017 10Q and Hires New Strategic Marketing Director 139
6.38 May 10, 2017: The Centers for Disease Control and Prevention Updated Guideline Now Include a Recommendation for Triclosan-Coated Sutures 140
6.39 May 03, 2017: Anika Reports First Quarter 2017 Financial Results 141
6.40 May 03, 2017: Covalon to Exhibit at the 2017 European Wound Management Association's Annual Conference 141
6.41 Apr 28, 2017: Sanofi Delivers Robust Q1 2017 Financial Results 142
6.42 Apr 28, 2017: Advanced Medical Solutions Group Reports 2016 Financial Results 149
6.43 Apr 27, 2017: Merit Medical Reports Results for First Quarter of 2017 149
6.44 Apr 27, 2017: Q1 2017 Sales Up 32% Over Q1 2016, for Wound Management Technologies 150
6.45 Apr 26, 2017: Baxter Reports First-Quarter 2017 Results and Increases Financial Outlook for Full-Year 2017 150
6.46 Apr 26, 2017: CryoLife Reports First Quarter 2017 Financial Results 152
6.47 Apr 26, 2017: The Medicines Company Reports First-Quarter 2017 Financial Results 153
6.48 Apr 25, 2017: Stryker reports first quarter 2017 results 154
6.49 Apr 19, 2017: Johnson & Johnson reports Q1 2017 results 155
6.50 Apr 18, 2017: Johnson & Johnson Reports 2017 First-Quarter Results 157
6.51 Apr 18, 2017: United Health Products to file late 2016 audited year end 159
6.52 Apr 16, 2017: Establishment of Lohmann & Rauscher Tunisie s.a.r.l. 159
6.53 Apr 12, 2017: Change in the B. Braun Management Board and the Aesculap Management Board 159
6.54 Apr 12, 2017: Sanofi appoints Nikhilesh Kalra to lead Consumer Healthcare business for India and South Asia 160
6.55 Apr 11, 2017: Sanofi Announces Pre-quarterly Results Communication 160
6.56 Apr 11, 2017: Z-Medica Products Approved For Use In Brazil 161
6.57 Apr 05, 2017: MPP Group Announces Launch Of Dextatic Advanced Wound Care Dressing 162
6.58 Apr 05, 2017: Sanofi Appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee 162
6.59 Apr 03, 2017: Baxter Unveils Design Enhancement to FLOSEAL Hemostatic Agent at AORN Meeting 163
6.60 Apr 03, 2017: Baxter Unveils Design Enhancement to TISSEEL Hemostatic Agent at AORN Meeting 163
6.61 Mar 31, 2017: B. Braun continues its sales and earnings growth 164
6.62 Mar 31, 2017: The Medicines Company Appoints Paris Panayiotopoulos to Its Board of Directors 166
6.63 Mar 21, 2017: SeeThruEquity Issues Report on United Health Products 166
6.64 Mar 14, 2017: New Data Indicates Use of Baxter's FLOSEAL in Cardiac and Spinal Surgeries May Be Associated with Lower Hospital Costs 168
6.65 Mar 14, 2017: Advanced Medical Solutions Group: Unaudited preliminary Results for the year ended 31 December 2016 169
6.66 Mar 13, 2017: Cook Medical Announces Umesh Patel as President of Cook Biotech 169
6.67 Mar 08, 2017: Wound Management announces appointment of John Siedhoff as Chairman 170
6.68 Mar 07, 2017: Anteo Technologies Announces Verification Study With Cook Medical Australia 171
6.69 Mar 02, 2017: Sanofi's Board of Directors Proposes Appointment of Melanie Lee, PhD and Bernard Charles as New Independent Directors 171
6.70 Feb 28, 2017: The Medicines Company Reports Fourth-Quarter and Full-Year 2016 Financial Results 172
6.71 Feb 22, 2017: Change in the B. Braun Management Board 174
6.72 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 174
6.73 Feb 21, 2017: Merit Medical Reports Results for Fourth Quarter and Year Ended December 31, 2016 177
6.74 Feb 16, 2017: Arch Therapeutics Provides Corporate Milestone Update, Including Anticipated Filing of 510(k) for AC5 178
6.75 Feb 15, 2017: CryoLife Reports Fourth Quarter and Full Year 2016 Financial Results 178
6.76 Feb 15, 2017: Anika Reports Fourth Quarter and Full Year 2016 Financial Results 179
6.77 Feb 15, 2017: Anika Therapeutics Reports 33% Revenue Growth in Third Quarter 2011 180
6.78 Feb 14, 2017: Wound Management Technologies Announces Record Quarterly and Annual Sales Ending December 31, 2016 - Up 147% over Q4 2015, and 63% over 2015 181
6.79 Feb 08, 2017: Sanofi Delivers 2016 Sales and Business EPS Growth at CER 182
6.80 Feb 08, 2017: Baxter Appoints Dr. Stephen Oesterle to Its Board 190
6.81 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 191
6.82 Feb 02, 2017: Arch Therapeutics Announces Issuance of Method-of-Use Patent Covering Self-Assembling Peptidomimetics 191
6.83 Feb 02, 2017: Arch Therapeutics Announces Issuance of Method-of-Use Patent Covering Self-Assembling Peptidomimetics 192
6.84 Feb 01, 2017: Sanofi Appoints Hugo Fry as General Manager UK 193
6.85 Feb 01, 2017: Baxter Reports 2016 Fourth-Quarter and Full-Year Results 194
6.86 Jan 30, 2017: Sanofi Appoints Kathleen Tregoning to Executive Committee and Executive Vice President, External Affairs 196
6.87 Jan 30, 2017: Covalon Posts Record First Quarter Financial Results 196
6.88 Jan 24, 2017: Stryker reports 2016 results and 2017 outlook 197
6.89 Jan 24, 2017: Johnson & Johnson Reports 2016 Fourth-Quarter Results 199
6.90 Jan 10, 2017: Stryker provides 2016 preliminary net sales results 201
6.91 Jan 09, 2017: Johnson & Johnson Medical Devices Companies Launch CareAdvantage, a Suite of Holistic, Insights-Driven Capabilities to Help U.S. Health Systems Navigate Value-Based Care 202
6.92 Jan 03, 2017: Covalon CEO Provides Update on Anticipated Fiscal 2017 Financial Growth 203
6.93 Dec 08, 2016: Wound Management Technologies Welcomes J. Michael Carmena as its New CFO 205
6.94 Dec 07, 2016: Biom'up receives CE Mark Approval for HEMOBLAST Bellows, the first active hemostatic powder for management of mild to moderate intra-operative bleedings 205
6.95 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 206
6.96 Nov 18, 2016: Dynasil and Cook Biotech Join Together to Advance Xcede Technologies Patch through First in Human Trials 209
6.97 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 210
6.98 Nov 03, 2016: ImageIQ Selected as Imaging CRO for CryoLife's PerClot Intraoperative Hemostasis Pivotal Clinical Trial 210
6.99 Nov 03, 2016: ImageIQ Selected as Imaging CRO for CryoLife's PerClot Intraoperative Hemostasis Pivotal Clinical Trial 211
6.100 Nov 01, 2016: Wound Management Technologies Reports Preliminary Financial Results For Q3 2016 Sales Up 56% over Q3 2015, and 2016 YTD Sales Up 41% over 2015 YTD Sales 211
6.101 Oct 31, 2016: Arch Therapeutics Reports AC5 Topical Hemostatic Device Successfully Stopped Bleeding in Patients on Antiplatelet Therapy in Recently Completed Clinical Study 211
6.102 Oct 28, 2016: Sanofi Announces Strong Q3 2016 Results 213
6.103 Oct 27, 2016: Stryker reports third quarter 2016 results 220
6.104 Oct 26, 2016: CryoLife Reports Third Quarter 2016 Financial Results 221
6.105 Oct 26, 2016: Anika Reports Third Quarter 2016 Financial Results 222
6.106 Oct 26, 2016: Merit Medical Reports Sales Up 15.3% for the Quarter Ended September 30, 2016 223
6.107 Oct 26, 2016: The Medicines Company Reports Third-Quarter 2016 Financial Results 223
6.108 Oct 25, 2016: Baxter Reports Third Quarter 2016 Results and Increases Financial Outlook For Full-Year 2016 225
6.109 Oct 25, 2016: James W. Bullock Joins CryoLife Board of Directors 226
6.110 Oct 24, 2016: Vascular Solutions Reports Third Quarter Results 226
6.111 Oct 18, 2016: Johnson & Johnson Reports 2016 Third-Quarter Results 229
6.112 Sep 30, 2016: Sanofi Appoints Alan Main to Executive Committee and Executive Vice President, Consumer Healthcare 231
7 Appendix 232
7.1 Methodology 232
7.2 About GlobalData 235
7.3 Contact Us 235
7.4 Disclaimer 235
1.1 List of Tables
Table 1: Wound Closure Hemostats - Pipeline Products by Stage of Development 13
Table 2: Wound Closure Hemostats - Pipeline Products by Segment 14
Table 3: Wound Closure Hemostats - Pipeline Products by Territory 15
Table 4: Wound Closure Hemostats - Pipeline Products by Regulatory Path 16
Table 5: Wound Closure Hemostats - Pipeline Products by Estimated Approval Date 17
Table 6: Wound Closure Hemostats - Ongoing Clinical Trials 18
Table 7: Hemostats Companies - Pipeline Products by Stage of Development 19
Table 8: Hemostats - Pipeline Products by Stage of Development 21
Table 9: 3-D Matrix Ltd Pipeline Products & Ongoing Clinical Trials Overview 23
Table 10: PuraStat Hemostat - Product Status 24
Table 11: PuraStat Hemostat - Product Description 24
Table 12: TDM-511 - Product Status 25
Table 13: TDM-511 - Product Description 25
Table 14: 3-D Matrix Ltd - Ongoing Clinical Trials Overview 26
Table 15: PuraStat Hemostat - A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of PuraStat Absorbable Haemostatic Material for the Management of Bleeding in Vascular Surgery 27
Table 16: PuraStat Hemostat - Randomized Controlled Trial Comparing Purastat to Standard Therapy for Haemostasis Control During Endoscopic Submucosal Dissection 27
Table 17: Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 28
Table 18: Hemostatic Patch - Product Status 28
Table 19: Hemostatic Patch - Product Description 28
Table 20: Arch Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 29
Table 21: AC5 Surgical Hemostatic Device - Product Status 29
Table 22: AC5 Surgical Hemostatic Device - Product Description 29
Table 23: AC5 Surgical Hemostatic Device - Internal Use - Product Status 30
Table 24: AC5 Surgical Hemostatic Device - Internal Use - Product Description 30
Table 25: Argon Medical Devices Inc Pipeline Products & Ongoing Clinical Trials Overview 31
Table 26: Hemaseel Thrombin Haemostatic Agent - Product Status 31
Table 27: Hemaseel Thrombin Haemostatic Agent - Product Description 31
Table 28: Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview 32
Table 29: Hemopatch - Product Status 32
Table 30: Hemopatch - Product Description 32
Table 31: Baxter International Inc - Ongoing Clinical Trials Overview 33
Table 32: Hemopatch - A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures on High Risk Population for Prolonged Air Leak (more than 5 Days - PAL) 34
Table 33: Hemopatch - A Prospective Randomized Trial of Hemopatch Versus No Hemopatch for the Intraoperative Hemostasis During Deceased Donor Renal Transplant 34
Table 34: Hemopatch - Phase III, Randomized, Unblinded, Controlled Clinical Trial for Evaluating the Effectiveness of the use of the New Hemostatic Patch Hemopatch in Patients undergoing Surgical Liver Resection 34
Table 35: Hemopatch - Prospective Randomized Clinical Trial to Prevent Air Leaks After Lung Resection with Hemopatch Sealing Hemostat: SEALLS (Sealing Evaluation of Air Leaks After Lung Surgery) Trial 35
Table 36: Hemopatch - Prospective, Multicenter, Open-label, Randomized, Phase III Clinical Trial of Prevention of Prolonged Air Leak after Lung Resection in High-risk Patients, Applying HEMOPATCH 35
Table 37: Beth Israel Deaconess Medical Center Inc Pipeline Products & Ongoing Clinical Trials Overview 36
Table 38: Portable Wound Hemostasis System - Product Status 36
Table 39: Portable Wound Hemostasis System - Product Description 36
Table 40: Biomedica Management Corp Pipeline Products & Ongoing Clinical Trials Overview 37
Table 41: ClotFoam - Product Status 37
Table 42: ClotFoam - Product Description 37
Table 43: ClotGel - Product Status 38
Table 44: ClotGel - Product Description 38
Table 45: ClotSpray - Product Status 38
Table 46: ClotSpray - Product Description 39
Table 47: Biom'Up SAS Pipeline Products & Ongoing Clinical Trials Overview 40
Table 48: Hemoblast Bellows - Product Status 40
Table 49: Hemoblast Bellows - Product Description 40
Table 50: Biom'Up SAS - Ongoing Clinical Trials Overview 41
Table 51: Hemoblast Bellows - Prospective, Randomized, Controlled, Multicenter, Pivotal, Clinical Investigation Evaluating the Safety and Efficacy of Hemoblast Bellows in Cardiothoracic, Abdominal, and Orthopedic Lower Extremity Surgeries 42
Table 52: C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 43
Table 53: New Hemostat 1 - Product Status 43
Table 54: New Hemostat 1 - Product Description 43
Table 55: New Hemostat 2 - Product Status 44
Table 56: New Hemostat 2 - Product Description 44
Table 57: Cellphire Inc Pipeline Products & Ongoing Clinical Trials Overview 45
Table 58: Thromboderm - Product Status 45
Table 59: Thromboderm - Product Description 45
Table 60: Thrombosomes - Hemostatic Agent - Product Status 46
Table 61: Thrombosomes - Hemostatic Agent - Product Description 46
Table 62: Ceramicos Para Aplicacoes Medicas Lda Pipeline Products & Ongoing Clinical Trials Overview 47
Table 63: HemoKi - Product Status 47
Table 64: HemoKi - Product Description 47
Table 65: Columbia University Pipeline Products & Ongoing Clinical Trials Overview 48
Table 66: Hemostatic Wound Dressing - Product Status 48
Table 67: Hemostatic Wound Dressing - Product Description 48
Table 68: Covalent Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 49
Table 69: CovaSTAT - Product Status 49
Table 70: CovaSTAT - Product Description 49
Table 71: Covalon Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 50
Table 72: ColActive THP - Product Status 50
Table 73: ColActive THP - Product Description 51
Table 74: CovaStat BioActive Absorbable Hemostatic Sponge - Product Status 51
Table 75: CovaStat BioActive Absorbable Hemostatic Sponge - Product Description 51
Table 76: Cresilon Inc Pipeline Products & Ongoing Clinical Trials Overview 52
Table 77: TRAUMAGEL - Product Status 52
Table 78: TRAUMAGEL - Product Description 52
Table 79: VETIGEL - Product Status 53
Table 80: VETIGEL - Product Description 53
Table 81: CryoLife Inc Pipeline Products & Ongoing Clinical Trials Overview 54
Table 82: PerClot - Product Status 54
Table 83: PerClot - Product Description 54
Table 84: CryoLife Inc - Ongoing Clinical Trials Overview 55
Table 85: PerClot - Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot Polysaccharide Hemostatic System 56
Table 86: Endomedix Incorporated Pipeline Products & Ongoing Clinical Trials Overview 57
Table 87: Surgical Hemostat - Intracranial Surgery - Product Status 57
Table 88: Surgical Hemostat - Intracranial Surgery - Product Description 57
Table 89: Topical Hemostat - Product Status 58
Table 90: Topical Hemostat - Product Description 58
Table 91: Entegrion Inc Pipeline Products & Ongoing Clinical Trials Overview 59
Table 92: Stasix - Product Status 59
Table 93: Stasix - Product Description 59
Table 94: Ethicon US LLC Pipeline Products & Ongoing Clinical Trials Overview 60
Table 95: Flowable thrombin - Product Status 60
Table 96: Flowable thrombin - Product Description 60
Table 97: Next Gen Hemostat Kit - Product Status 61
Table 98: Next Gen Hemostat Kit - Product Description 61
Table 99: SURGIFLO - Sterile Field Preparation - Product Status 61
Table 100: SURGIFLO - Sterile Field Preparation - Product Description 62
Table 101: Gamma Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 63
Table 102: GammaTF - Product Status 63
Table 103: GammaTF - Product Description 63
Table 104: gel-e Inc Pipeline Products & Ongoing Clinical Trials Overview 64
Table 105: Hemogrip Spray-On Foam - Product Status 64
Table 106: Hemogrip Spray-On Foam - Product Description 64
Table 107: Vascular gel-e - External Wounds - Product Status 65
Table 108: Vascular gel-e - External Wounds - Product Description 65
Table 109: Vascular gel-e - Internal Surgical Use - Product Status 65
Table 110: Vascular gel-e - Internal Surgical Use - Product Description 65
Table 111: Haemostatix Ltd Pipeline Products & Ongoing Clinical Trials Overview 66
Table 112: HaemoPlax - Product Status 66
Table 113: HaemoPlax - Product Description 66
Table 114: PeproStat - Product Status 67
Table 115: PeproStat - Product Description 67
Table 116: Haemostatix Ltd - Ongoing Clinical Trials Overview 68
Table 117: PeproStat - A Controlled, Randomized, Multi-center, Double Blind, Phase II Study to Evaluate Efficacy and Safety of Topical PeproStat in Intraoperative Surgical Haemostasis 69
Table 118: Hemostasis LLC Pipeline Products & Ongoing Clinical Trials Overview 70
Table 119: ENT Hemostat - Product Status 70
Table 120: ENT Hemostat - Product Description 70
Table 121: Hemostatic Gel - Product Status 71
Table 122: Hemostatic Gel - Product Description 71
Table 123: KeraNetics, LLC Pipeline Products & Ongoing Clinical Trials Overview 72
Table 124: Keratin-Based Hemostat - Product Status 72
Table 125: Keratin-Based Hemostat - Product Description 72
Table 126: LifeBond Ltd Pipeline Products & Ongoing Clinical Trials Overview 73
Table 127: Absorbable Hemostats - Product Status 73
Table 128: Absorbable Hemostats - Product Description 73
Table 129: LifePatch Heavy - Product Status 74
Table 130: LifePatch Heavy - Product Description 74
Table 131: LifePatch Surgery - Product Status 74
Table 132: LifePatch Surgery - Product Description 75
Table 133: Resorba GmbH Pipeline Products & Ongoing Clinical Trials Overview 76
Table 134: Antibiotic Hemostat - Product Status 76
Table 135: Antibiotic Hemostat - Product Description 76
Table 136: GENTA-COLL Resorb - Product Status 77
Table 137: GENTA-COLL Resorb - Product Description 77
Table 138: GENTA-FOIL Resorb - Product Status 77
Table 139: GENTA-FOIL Resorb - Product Description 78
Table 140: KOLLAGEN resorb - Product Status 78
Table 141: KOLLAGEN resorb - Product Description 78
Table 142: RESORBA CELL Fibrillar - Product Status 79
Table 143: RESORBA CELL Fibrillar - Product Description 79
Table 144: RESORBA CELL forte - Product Status 79
Table 145: RESORBA CELL forte - Product Description 80
Table 146: RESORBA CELL standard - Product Status 80
Table 147: RESORBA CELL standard - Product Description 80
Table 148: Rice University Pipeline Products & Ongoing Clinical Trials Overview 81
Table 149: KOD Hydrogel Hemostat - Product Status 81
Table 150: KOD Hydrogel Hemostat - Product Description 81
Table 151: Samyang Biopharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview 82
Table 152: B6102 - Hemostat - Product Status 82
Table 153: B6102 - Hemostat - Product Description 82
Table 154: Sanofi Pipeline Products & Ongoing Clinical Trials Overview 83
Table 155: LeSeal - Product Status 83
Table 156: LeSeal - Product Description 83
Table 157: Lumagel - Product Status 84
Table 158: Lumagel - Product Description 84
Table 159: Sea Run Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 85
Table 160: SEA-STAT - Product Status 85
Table 161: SEA-STAT - Product Description 85
Table 162: St Teresa Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 86
Table 163: SURGICLOT - Product Status 86
Table 164: SURGICLOT - Product Description 86
Table 165: WRAPCLOT - Product Status 87
Table 166: WRAPCLOT - Product Description 87
Table 167: The Medicines Company Pipeline Products & Ongoing Clinical Trials Overview 88
Table 168: Fibropad Patch - Product Status 88
Table 169: Fibropad Patch - Product Description 88
Table 170: Therus Corporation Pipeline Products & Ongoing Clinical Trials Overview 89
Table 171: Therus Acoustic Hemostasis System - Product Status 89
Table 172: Therus Acoustic Hemostasis System - Product Description 89
Table 173: Thrombotargets Corp Pipeline Products & Ongoing Clinical Trials Overview 90
Table 174: Next Generation TT-173 - Product Status 90
Table 175: Next Generation TT-173 - Product Description 90
Table 176: TT-173 - Product Status 91
Table 177: TT-173 - Product Description 91
Table 178: United Health Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview 92
Table 179: HemoStyp General Surgeries Gauze - Product Status 92
Table 180: HemoStyp General Surgeries Gauze - Product Description 92
Table 181: HemoStyp Internal And External Procedure Gauze - Product Status 93
Table 182: HemoStyp Internal And External Procedure Gauze - Product Description 93
Table 183: HemoStyp Trauma Gauze - Product Status 93
Table 184: HemoStyp Trauma Gauze - Product Description 94
Table 185: University of Grenoble Alpes Pipeline Products & Ongoing Clinical Trials Overview 95
Table 186: Bleeding Controlling Device - Product Status 95
Table 187: Bleeding Controlling Device - Product Description 95
Table 188: Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview 96
Table 189: BioHemostat - Product Status 96
Table 190: BioHemostat - Product Description 96
Table 191: Wound Management Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 97
Table 192: HemaQuell - Product Status 97
Table 193: HemaQuell - Product Description 97
Table 194: Xcede Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 98
Table 195: Xcede - Femoral Artery - Product Status 98
Table 196: Xcede - Femoral Artery - Product Description 98
Table 197: Xcede - Laparoscopic Surgery - Product Status 99
Table 198: Xcede - Laparoscopic Surgery - Product Description 99
Table 199: Xcede - Vascular Surgery - Product Status 99
Table 200: Xcede - Vascular Surgery - Product Description 100
Table 201: Xcede Hemostatic Patch - Product Status 100
Table 202: Xcede Hemostatic Patch - Product Description 100
Table 203: Glossary 234
1.2 List of Figures
Figure 1: Wound Closure Hemostats - Pipeline Products by Stage of Development 13
Figure 2: Wound Closure Hemostats - Pipeline Products by Segment 14
Figure 3: Wound Closure Hemostats - Pipeline Products by Territory 15
Figure 4: Wound Closure Hemostats - Pipeline Products by Regulatory Path 16
Figure 5: Wound Closure Hemostats - Pipeline Products by Estimated Approval Date 17
Figure 6: Wound Closure Hemostats - Ongoing Clinical Trials 18
